Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

Nature Communications

Volumn 7, Issue , 2016, Pages

  Merlevede, Jane ^a   Droin, Nathalie ^a,b   Qin, Tingting ^c   Meldi, Kristen ^c   Yoshida, Kenichi ^d   Morabito, Margot ^a   Chautard, Emilie ^e   Auboeuf, Didier ^f   Fenaux, Pierre ^g   Braun, Thorsten ^h   Itzykson, Raphael ^g   De Botton, Stéphane ^a   Quesnel, Bruno ⁱ   Commes, Thérèse ^j   Jourdan, Eric ^k   Vainchenker, William ^a   Bernard, Olivier ^a   Pata Merci, Noemie ^b   Solier, Stéphanie ^a   Gayevskiy, Velimir ^l   Dinger, Marcel E ^l   Cowley, Mark J ^l   Selimoglu Buet, Dorothée ^a   Meyer, Vincent ^m   Artiguenave, François ^m   Deleuze, Jean François ^m   Preudhomme, Claude ⁱ   Stratton, Michael R ⁿ   Alexandrov, Ludmil B ^n,o,p   Padron, Eric ^q   Ogawa, Seishi ^d   Koscielny, Serge ^a   Figueroa, Maria ^c   Solary, Eric ^a,r   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CNRS UMS3655   (France)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d KYOTO UNIVERSITY   (Japan)

^e UNIVERSITÉ LYON 1   (France)

^f CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h AVICENNE HOSPITAL   (France)

ⁱ JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^j UNIV MONTPELLIER   (France)

^k NÎMES UNIVERSITY HOSPITAL   (France)

^l GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^m CENTRE NATIONAL DE GÉNOTYPAGE   (France)

ⁿ WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^o LOS ALAMOS NATIONAL LABORATORY   (United States)

^p CENTER FOR NONLINEAR STUDIES   (United States)

^q H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^r UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADDITIONAL SEX COMBS LIKE 2 PROTEIN; ATP BINDING CASSETTE SUB FAMILY C MEMBER 9 PROTEIN; AZACITIDINE; CD14 ANTIGEN; CD34 ANTIGEN; CONNECTIN; CYTOSINE; DECITABINE; DEDICATOR OF CYTOKINESIS PROTEIN 2; DNA; NEUROFIBROMIN; PHD FINGER PROTEIN 6; PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE;

ALLELE; CANCER; DRUG; GENE EXPRESSION; GENETIC ANALYSIS; METHYLATION; MUTATION;

ADULT; ALLELE; ARTICLE; BONE MARROW CELL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; EXOME; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MIDDLE AGED; MONOCYTE; PROMOTER REGION; RNA SEQUENCE; SOMATIC MUTATION; WHOLE EXOME SEQUENCE; WHOLE GENOME SEQUENCE; AGED; ANALOGS AND DERIVATIVES; CELL SURVIVAL; DNA SEQUENCE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HEK293 CELL LINE; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MUTATION; SEQUENCE ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL SURVIVAL; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MUTATION; SEQUENCE ANALYSIS, DNA; SEQUENCE ANALYSIS, RNA;

EID: 84959419471     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10767     Document Type: Article

References (67)

1. Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937-951 (2009).
2. Padron, E. & Steensma, D. P. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies. Curr. Opin. Hematol. 22, 163-170 (2015).
3. Jankowska, A. M. et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118, 3932-3941 (2011).
4. Itzykson, R. et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 121, 2186-2198 (2013).
5. Kon, A. et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat. Genet. 45, 1232-1237 (2013).
6. Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64-69 (2011).
7. Gelsi-Boyer, V. et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 8, 299 (2008).
8. Kosmider, O. et al. Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. Leukemia 27, 1946-1949 (2013).
9. Dunbar, A. J. et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 68, 10349-10357 (2008).
10. Gómez-Seguí, I. et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. Leukemia 27, 1943-1946 (2013).
11. Klinakis, A. et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473, 230-233 (2011).
12. Singh, H. et al. Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies. Blood Cancer J. 3, e117 (2013).
13. Gambacorti-Passerini, C. B. et al. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood 125, 499-503 (2015).
14. Itzykson, R. et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J. Clin. Oncol. 31, 2428-2436 (2013).
15. Patnaik, M. M. et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia 28, 2206-2212 (2014).
16. Navada, S. C., Steinmann, J., Lübbert, M. & Silverman, L. R. Clinical development of demethylating agents in hematology. J. Clin. Invest. 124, 40-46 (2014).
17. Tsai, H. C. et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21, 430-446 (2012).
18. Braun, T. et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 118, 3824-3831 (2011).
19. Selimoglu-Buet, D. et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood 125, 3618-3626 (2015).
20. Hinson, J. T. et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science 349, 982-986 (2015).
21. Quesada, V. et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44, 47-52 (2011).
22. Palomero, T. et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat. Genet. 46, 166-170 (2014).
23. Abdel-Wahab, O. et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114, 144-147 (2009).
24. Ko, M. et al. TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol. Rev. 263, 6-21 (2015).
25. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246-259 (2013).
26. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
27. Horn, S. et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959-961 (2013).
28. Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505-511 (2015).
29. Melton, C., Reuter, J. A., Spacek, D. V. & Snyder, M. Recurrent somatic mutations in regulatory regions of human cancer genomes. Nat. Genet. 47, 710-716 (2015).
30. Andersson, R. et al. An atlas of active enhancers across human cell types and tissues. Nature 507, 455-461 (2014).
31. Cheson, B. D. et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108, 419-425 (2006).
32. Mohamedali, A. M. et al. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia 29, 1928-1938 (2015).
33. Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488-2498 (2014).
34. Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477-2487 (2014).
35. Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472-1478 (2014).
36. Jan, M. et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia 4. Sci. Transl. Med. 20, 149ra118 (2012).
37. Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328-333 (2014).
38. Potter, N. E. & Greaves, M. Cancer: Persistence of leukaemic ancestors. Nature 506, 300-301 (2014).
39. Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25-38 (2011).
40. Itzykson, R. & Solary, E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia 27, 1441-1450 (2013).
41. Sakaguchi, H. et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat. Genet. 45, 937-941 (2013).
42. Craddock, C. et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 27, 1028-1036 (2013).
43. Shen, Q. et al. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur. J. Haematol. 95, 168-176 (2015).
44. Figueroa, M. E. et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114, 3448-3458 (2009).
45. Aucagne, R. et al. Transcription intermediary factor 1g is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J. Clin. Invest. 121, 2361-2370 (2011).
46. Meldi, K. et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J. Clin. Invest. 125, 1857-1872 (2015).
47. Treppendahl, M. B., Kristensen, L. S. & Gronbak, K. Predicting response to epigenetic therapy. J. Clin. Invest. 124, 47-55 (2014).
48. Goodyear, O. et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116, 1908-1918 (2010).
49. Yang, H. et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28, 1280-1288 (2014).
50. Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961-973 (2015).
51. Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974-986 (2015).
52. Licht, J. D. DNA methylation inhibitors in cancer therapy: the immunity dimension. Cell 162, 938-939 (2015).
53. Montenegro, M. F. et al. Targeting the epigenetic machinery of cancer cells. Oncogene 34, 135-143 (2015).
54. Campbell, R. M. & Tummino, P. J. Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J. Clin. Invest. 124, 64-69 (2014).
55. Yoshida, K. et al. The landscape of somatic mutations in Down syndromerelated myeloid disorders. Nat. Genet. 45, 1293-1299 (2013).
56. Koboldt, D. C. et al. Var Scan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
57. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114-2120 (2014).
58. Hua, X. et al. DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. Am. J. Hum. Genet. 93, 439-451 (2013).
59. Larson, D. E. et al. Somatic Sniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28, 311-317 (2012).
60. Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811-1817 (2012).
61. Fuentes Fajardo, K. V. et al. Detecting false-positive signals in exome sequencing. Hum. Mutat. 33, 609-613 (2012).
62. Kim, D. et al. Top Hat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
63. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
64. Anders, S., Pyl, P. T. & Huber, W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166-169 (2015).
65. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2. Genome Biol. 15, 550 (2014).
66. Park, Y., Figueroa, M. E., Rozek, L. S. & Sartor, M. A. Methyl Sig: a whole genome DNA methylation analysis pipeline. Bioinformatics 30, 2414-2422 (2014).
67. Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571-1572 (2011).